Pfizer of the USA and Eisai of Japan have formed a strategic alliance for the development of new drugs to treat Alzheimer's disease and other cognitive disorders. Eisai's E2020, an acetylcholinesterase inhibitor, will be the lead agent in this new agreement. Pfizer already has its own in-house developed acetylcholinesterase inhibitor, codenamed CP-118,954, in Phase II trials (see later) and this may also be included in the collaboration with Eisai.
The two companies will copromote E2020 in major markets in Europe and the USA, and Pfizer holds an exclusive license to the drug in certain other commercially-important countries, such as Canada and Australia. In addition, as part of the agreement the companies will also form a joint committee to plan development of other dementia agents, including CP-118,954. Eisai will market E2020 through a joint promotion with Pfizer in the USA, UK, Germany and France.
"E2020 has demonstrated excellent clinical potential and a favorable safety and toleration profile in early studies," said Pfizer. The drug is in mid-Phase III trials in the USA, early Phase III trials in Europe and late Phase II trials in Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze